reason report
pt
bottom line morn report top- bottom-
line beat vs consensu increas ep guidanc
reflect stronger oper result us humira sale
weaker quarter miss off-set currenc
signific uptak compani new hcv product mavyret
us initi ex-u countri plan repurchas
stock asr begin may take advantag
stock price correct follow rova-t setback still
remain exist buy-back author open
market purchas could lower share count increas
ep stretch current cash
resourc manag signal opportunist buy-back
activ alter willing execut acquisit licens
arrang revis ep guidanc recent
consensu mid-point expect commensur increas
consensu near futur well beat throughout
year compani appear continu momentum
oncolog product share partner hcv
activ share buy-back see stock support least
next month result humira like close
scrutin particularli given mani launch underway come
competit inflammatori diseas indic defend
profil jak inhibitor upadacitinib strongli call
far least seem avoid liabil baricitinib
becam appar week fda advisori committe
updat model reflect stronger oper guidanc
increas pro-forma dilut ep
lower price target reflect
contract peer multipl maintain market perform rate
abbvi stock abbvi stock benefit compani share
repurchas next week although would expect trade
back toward today rang upon complet
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
compani inform leerink partner llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target per share stock rate market perform
transit corpor ownership success independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil growth rate matur biotechnolog compani remain
highli depend singl franchis humira sale total sale
suggest us valuat still discount compar diversifi peer
us biosimilar settlement competitor appear reassur investor
fear biosimilar entri exagger invalid expect oncolog product
imbruvica venclexta becom signific product gener
revenu compani next-gener hcv regimen boost
market share consider declin market look compani array
promis late-stag clinic medicin inflamm metabol diseas struggl
expand oncolog franchis beyond imbruvica venclexta current pipelin product
contribut revenu growth unlik materi dilut massiv
headwind face biosimilar enter market compet humira
ex-u humira hcv support top-lin total product revenu
beat consensu line estim humira revenu
qoq line consensu estim result due
us inventori draw-down off-set one-tim ex-u shipment currenc
tailwind ex-u sale expect inventori level remain lower
lower us humira guidanc compar previous total
imbruvica revenu qoq consensu forecast
imbruvica sale us intern profit share
quarter total hcv revenu mavyret/viekira qoq significantli ahead
consensu estim mavyret finish share
us market ex-u mavyret benefit wareh japanes patient prior
antivir failur manag guidanc full-year global hcv sale impli
continu strength remain quarter product sale mostli mix
quarter signific outlier consensu kaletra lupron
addit expens off-set tax rate ep oper expens
higher consensu expect non-gaap expens
less consensu estim non-gaap sg expens
higher consensu estim result
oper margin consensu line estim howev
despit increas expens compar expect tax rate lower
compar consensu result non-gaap dilut ep beat consensu
estim averag dilut share outstand reduc
prior quarter
one-quart humira growth due currenc tailwind despit robust annual
growth humira note growth due favor currenc tailwind
call manag disclos us humira growth neg impact due
channel inventori destock howev ex-u humira sale boost due
time tender due currenc translat therefor calcul organ
growth humira annual exhibit like mani specialti
therapeut humira appear affect increment gross net adjust
year undermin sale growth compar prior period expect effect
larg dissip later year
earn guidanc increas reflect oper momentum base stronger
oper result quarter expect adjust ep rang
compar consensu updat estim
expect total revenu reach includ favor
currenc tailwind howev also plan increas invest pipelin
newly-launch product decreas project oper margin
also updat initi product level revenu guidanc key franchis humira
mavyret compani expect humira grow us prior due
channel inventori headwind expect ex-u humira sale
due larg currenc benefit total hcv revenu expect
increas prior guidanc
biggest upadacitinib trial set releas import launch expect
year import remain catalyst data last phase
upadacitinib monotherapi methotrex monotherapi treatment-nav patient
provid best character upadacitinib liabil lack thereof venou
thromboembol event vte similarli baricitinib fda regulatori decis come
month import read-through jak inhibitor stock two
critic event stock year approv launch elagolix
endometriosi venclexta r/r cll elagolix approv recent regulatori
delay review new liver safeti data stock see upsid new venclexta
approv broader cll popul increas drug revenu materi level
would requir disclosur earn press releas first time view stock
attract recent rang fail see enough upsid rang chang
stanc recommend
model updat captur leverag hcv sale ep increas pt
follow result guidanc revis revenu earn forecast
better reflect compani outlook decreas forecast humira
reflect cautiou commentari us growth ex-
us biosimilar eros increas revenu forecast mavyret near term
captur bolu patient addit increas forecast long term
also made signific neg chang kaletra syntroid total revenu
forecast increas minim chang decreas
updat total revenu forecast recent consensu
decreas vs consensu continu forecast oper margin
decreas estim margin reflect
compani expect invest commerci launch sever late stage pipelin asset
time frame forecast still assum signific growth
despit would expect save conclus larg
develop program upadacitinib risankizumab elagolix pro-forma dilut ep
forecast increas remain recent
consensu pro-forma dilut ep consensu
net result adjust chang sector valuat multipl bring target
price previous
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk rhhbi sni nv celg
averag consensu ep multipl appli current ep estim
give valu use revenu multipl similar
compani consensu sale appli revenu estim
give valu lastli dcf valuat given wacc
termin cash flow growth rate begin humira biosimilar entri give
present valu averag three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi assum oper margin increas current level
toward fail reach sustain level would advers affect
forecast valuat also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
non-gaap cost good sold
interest expens
abbvi guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time event
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
million
leerink partner research compani file
million
good sold
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep rhhbi sni celg
leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
mid-term growth tail risk celg
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current leerink dcf marketed/l stage program
sourc leerink partner estim compani file factset
